InterMune, Inc., a biotechnology company, focuses on the research, development, and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease in the United States. The companyÂ’s product candidates include Pirfenidone, which is in phase III clinical trials for the treatment of idiopathic pulmonary fibrosis; and ITMN-191, a hepatitis C virus protease inhibitor that is in Phase Ib clinical trials to treat patients with HCV infections. It has license and collaboration agreements with Hoffmann-LaRoche, Inc. and F. Hoffmann-LaRoche, Ltd.; Genentech, Inc.; Connetics Corporation; Boehringer Ingelheim International GmbH; Novartis Corporation; Array BioPharma, Inc.; Eli Lilly & Company; and ALZA Corporation. The company was founded in 1998 and is headquartered in Brisbane, California.
$14.4 (03/02/09)
